Targeting Inflammation–Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension Authors: Siyuan Song, Jing Wu, Mengyuan Yin, Yuanping Shi Published: 2026 ABSTRACT AbstractPulmonary arterial hypertension (PAH) is a cardiovascular disease characterized by a hidden or insidious onset with symptoms including dyspnea and heart failure, which can result in sudden death. Inflammation and oxidative stress are key factors in the pathogenesis of PAH. Hence, anti-inflammatory and antioxidant agents are promoted as therapeutically beneficial. However, the efficacy and safety of these therapeutics are limited by poor solubility and stability, short half-life, lack of targeting capability, and significant side effects. The pulmonary vasculature of patients with PAH exhibits highly heterogeneous blood flow distribution, characterized by reduced wall shear stress and vortex formation at pulmonary artery bifurcations. Abnormal shear stress impairs endothelial function and induces progressive pulmonary vascular remodeling. Combined with endothelial barrier dysfunction, these hemodynamic alterations collectively govern the adhesion, retention and transmural transport of nanocarriers within diseased blood vessels. Nanocarriers (NCs) including liposomes, polymeric and exosomes, through intelligent responsiveness, combination therapy, and personalized and precision delivery strategies, can significantly enhance drug stability, prolong half-life, achieve specific targeting of pulmonary lesions, and reduce side effects. In addition, local administration methods, such as aerosol inhalation and intratracheal instillation, can achieve efficient drug accumulation in the lungs, thereby reducing systemic toxicity. This review summarizes the latest advances in the application of NCs to deliver anti-inflammatory and antioxidant agents for the treatment of PAH, and sorts out multiple translational bottlenecks identified in preclinical investigations. These critical challenges include rapid pulmonary clearance of inhaled nanoformulations, unclear long-term safety after repeated administration, low scalable production yield of nanocarriers, poor storage stability of preparations, inconsistent drug encapsulation efficiency, and unclarified in vivo action mechanisms. It provides solid theoretical support to address the above translational hurdles and advance precision clinical therapy for PAH. Introduction Pulmonary hypertension (PH) is hemodynamically defined as resting mean pulmonary artery pressure > 20 mmHg by right heart catheterization. The pathological hallmarks of PH include pronounced pulmonary vascular remodeling and progressive elevation of pulmonary vascular load, ultimately leading to right ventricular remodeling and even failure.1 Among the five clinical subgroups of PH, pulmonary arterial hypertension (PAH), accounting for 10%–15% of cases, is characterized by remodeling of the pulmonary arterial wall and formation of plexiform lesions. The diagnostic criteria for PAH are pulmonary artery wedge pressure ≤ 15 mmHg and pulmonary vascular resistance > 3 Wood units.2 Various diseases that can cause complications of PAH may manifest with nonspecific symptoms, especially exertional dyspnea and chest pain, often leading to delayed diagnosis. Therefore, early and accurate diagnosis and timely treatment are crucial to improve the survival of PAH patients. The United States Food and Drug Administration has approved multiple pharmacological agents for the treatment of PAH, which predominantly target the endothelin, nitric oxide (NO), and prostacyclin pathways.3 The pulmonary microenvironment in PAH presents distinctive physicochemical properties, prominently featuring elevated local reactive oxygen species (ROS), increased vascular permeability, and heterogeneous expression of endothelial surface receptors. Impaired function of BMPR2 or ATM drives excessive ROS production in pulmonary arterial endothelial cells, and a sharp ROS burst occurs at the early reoxygenation stage post hypoxia, which aggravates DNA damage and impairs endothelial repair, breaking the redox balance of lung vessels.4 Meanwhile, overactivated VEGF‑A/VEGFR2 signaling upregulates VEGFR2 phosphorylation, triggering VE‑cadherin phosphorylation and internalization to disrupt endothelial adherens junctions, widen intercellular gaps and raise vascular leakage of macromolecules, thus severely compromising endothelial barrier integrity.5 In addition, endothelial receptors display evident spatial heterogeneity: VEGFR2 is highly expressed in lesional endothelium, while markers including ACVRL1 and ENG are downregulated in certain PAH models. These unique microenvironmental characteristics lay a theoretical foundation for developing oxidative stress-responsive nanocarriers and endothelium-targeted delivery systems. Nevertheless, due to the heterogeneous expression of endothelial biomarkers, targeted ligands must be rationally screened and validated according to specific lesion locations and endothelial subtypes. The poor clinical translational performance of conventional small-molecule anti-inflammatory and antioxidant drugs for PAH mainly stems from inherent pharmacokinetic drawbacks, including weak pulmonary first-pass accumulation and excessive plasma protein binding, which prevent their wide application in routine PAH clinical guidelines. The present review sequentially delineates the roles of inflammation and oxidative stress (OS) in the pathogenesis of PAH, describes effective anti-inflammatory and antioxidant agents, and explores nanocarrier-based anti-inflammatory and antioxidant therapeutics, in addition to optimization of recent strategies for nano-delivery systems, as novel approaches for treatment of PAH. Distinct from previous reviews, this paper emphatically compares the major challenges for clinical translation, therapeutic advantages and main limitations of different drug-loaded nanocarriers. Inflammation and OS in PAH The pulmonary artery is composed of three layers: the intima, media, and adventitia. Pathological alterations in PAH predominantly affect the distal pulmonary arteries, manifesting as intimal dysfunction, medial thickening, as well as adventitial hyperplasia and fibrosis, concomitant with infiltration of inflammatory cells and remodeling of the extracellular matrix.6 Pulmonary artery endothelial cells (PAECs) serve pivotal roles in modulating vascular permeability, vascular tone, antithrombotic activity, and anti-inflammatory responses.7 Dysfunction of PAECs is precipitated by hemodynamic shear stress, hypoxia, increased production of inflammatory cytokines, and pharmacological insults, culminating in infiltration of inflammatory cells and aberrant proliferation of vascular cells.8,9 As PAH progresses, the pulmonary arterial pathologies precipitate hypertrophy of the right ventricle (RV), whereas appropriate functioning of the RV is a critical determinant of prognosis and survival.10 Immunological alterations are considered to be a critical contributing factor in vascular remodeling. The organized infiltration of lymphoid follicles, T lymphocytes, and B lymphocytes, coupled with upregulation of pro-inflammatory cytokines, underscores the fundamental role of inflammation in the pathogenesis of PAH.11 The pathological manifestations concomitant with PAH are characterized by infiltration of the pulmonary vasculature by inflammatory cells, where inflammatory responses stimulate aberrant proliferation and migration of vascular cells, and promote the acquisition of an apoptosis-resistant phenotype.12 ROS and reactive nitrogen species, encompassing hydroxyl radicals, superoxide anions, hydrogen peroxide, NO, and peroxynitrite anions, are free radicals intimately associated with OS.13 Physiological levels of ROS are essential to maintain normal cellular homeostasis, whereas excessive accumulation compromises cellular and organ integrity.14 Excessive production of ROS, together with an imbalance in bioactive intermediates or regulatory processes, leads to the development of OS,15 which promotes dysfunction of the pulmonary vascular endothelium, while reducing production and increasing degradation of NO, whereas accumulation of superoxide anions further decreases the bioavailability of NO and facilitates uncoupling of endothelial nitric oxide synthase (eNOS).7,16 Furthermore, OS contributes to the pathogenesis of PAH by inducing the secretion of inflammatory mediators, such as transforming growth factor-β, thereby inducing phenotypic switching of vascular cells.17 NF-κB and Nrf2 function as core molecular switches mediating the crosstalk between oxidative stress and inflammation in PAH. Hypoxia and reactive oxygen species accumulation concurrently activate HIF‑1α and NF‑κB, which collaboratively bridge oxidative stress and inflammation. HIF‑1α integrates hypoxic stimuli, redox disturbance and inflammatory signals, while NF‑κB further amplifies inflammation, endothelial‑mesenchymal transition (EndMT) and aberrant proliferation of vascular cells; both pathways downregulate BMPR2. Loss of BMPR2 signaling in turn aggravates oxidative stress, inflammation and vascular remodeling. The antagonistic Nrf2/HO‑1 pathway serves as a crucial protective regulator within the oxidative‑inflammatory axis, alleviating oxidative damage and pathological vascular remodeling via antioxidant and anti‑inflammatory actions.18 Anti-Inflammatory and Antioxidant Agents Since the pathogenesis of PAH is intricately linked to inflammatory processes, immunomodulatory and antioxidant pharmacological interventions are particularly efficacious for therapeutic management. A spectrum of immune cells, including T lymphocytes, B lymphocytes, macrophages, dendritic cells, and natural killer cells, has been implicated in the initiation and progression of PAH.19 Anti-inflammatory and antioxidant agents inhibit functioning of the pulmonary vascular endothelium through the attenuation of OS and inflammatory cascades,20 consequently mitigating pulmonary arterial inflammation and enhancing performance of the RV to optimize clinical outcomes. These findings underscore the substantial therapeutic potential of immune-targeted interventions for management of PAH. Immunomodulatory agents, antibody-based biologics, antioxidant therapeutics, and low-molecular-weight pharmacological agents are promising approaches for clinical treatment of PAH. We systematically summarize the research advances of anti-inflammatory and antioxidant therapeutics against PAH, and the relevant content is visually illustrated in Scheme 1. Scheme 1Anti-inflammatory and antioxidant therapeutics for PAH.A circular infographic wheel titled, Anti-inflammatory and Antioxidant drugs for PAH. The center title is surrounded by an inner ring of therapeutic categories and an outer ring listing example drugs for each category. Antibody-Based Biologics: Inhibition of Inflammatory Response. Examples: Tocilizumab; TNF-alpha Antagonist. Antioxidant Therapeutics: Attenuation of Inflammatory Stress. Examples: 4-phenylbutyric acid; Mirabegron; EOLC; EM; NDS. Flavonoid Compounds: Anti-Pulmonary Artery Remodeling; Anti-inflammatory. Examples: Dihydromyricetin; Sildenafil. Statin: Improvement of Right Ventricular Remodeling. Example: Simvastatin. Polyphenolic Compounds: Antioxidant and Anti-inflammatory. Examples: Resveratrol; Catechin; Quercetin; Anthocyanin. NSAIDs: Anti-inflammatory Regulation of Vascular Function. Example: Aspirin. Immuno-modulatory Agents: Regulation of Immune Response. Examples: Rapamycin; Rituximab; NLRP3 Inhibitors.A circular infographic wheel of anti-inflammatory and antioxidant drugs for PAH by therapeutic role. Anti-inflammatory and antioxidant therapeutics for PAH. Immunomodulatory Agents Rapamycin, a potent immunosuppressive agent, inhibits activation of T and B lymphocytes, thereby serving as a therapeutic modality for autoimmune disorders.21 In the context of PAH, rapamycin additionally attenuates secretion of inflammatory cytokines via downregulation of the pro-inflammatory transcription factor nuclear factor-kappa B (NF-κB) in pulmonary artery smooth muscle cells (PASMCs) (Figure 1A).22 Rituximab, a chimeric monoclonal antibody targeting CD20-positive B lymphocytes, induces B cell depletion, thereby diminishing autoantibody production and immune complex formation. Concurrently, rituximab suppresses generation of pro-inflammatory cytokines by innate immune cells, notably dendritic cells and macrophages, thereby eliciting profound anti-inflammatory effects (Figure 1B).23 Macrophage infiltration in PAH pathophysiology precipitates elevated expression of NOD-like receptor family pyrin domain containing 3 (NLRP3), inflammasome activation, and subsequent secretion of interleukin (IL)-1β (Figure 1C).24 Preclinical investigations have demonstrated that pharmacological inhibition of the NLRP3 signaling cascade ameliorates abnormal functioning of the RV in experimental models, suggesting that targeted modulation of this pathway represents a promising therapeutic strategy for PAH intervention (Figure 1D–F).25 Figure 1Immunomodulators alleviate PAH by reducing the secretion of inflammatory cytokines. (A) Schematic diagram showing activation of the mTORC1/NFκB/DPP4 signaling pathway in hypoxia-induced PH. Copyright 2019, Springer. (B) Nanoscale drug delivery systems for PAH immunotherapy. Copyright 2021, Elsevier. (C) Model of the caspase-8 canonical inflammasome pathway in the pathogenesis of PAH. Copyright 2022, Williams and Wilkins. (D) Cardiac function was improved in the MCT-MCC950 group by treatment with the NLRP3 inhibitor MCC950, as compared to rats treated with the vehicle (MCT-V) (n =8 phosphate-buffered saline, 8 MCT-V, and 11 MCT-MCC950), as demonstrated by increased tricuspid annular plane systolic excursion (P = 0.016), cardiac output (P = 0.042), and cardiac index (P = 0.025). There was also a significant improvement in systolic pressure of the RV (P = 0.043) and pulmonary artery acceleration time (P = 0.022). (E) Histological assessment of the pulmonary arterioles by staining with hematoxylin and eosin (n = 3 rats/group; > 20 arterioles/rat). MCC950 treatment reduced the percent median wall thickness of the pulmonary arteries in MCT rats as compared to controls (P < 0.0001 comparing rats or arterioles). Scale bars, 20 μm. (F) Western blot assay showing significantly lower expression of NLRP3 (P = 0.035) and cleaved IL-1β (P = 0.0082) in the RVs of MCT rats treated with MCC950 as compared to the vehicle only group (n = 5 phosphate-buffered saline, 6 MCT-V, and 7 MCT-MCC950 rats). The content of target proteins was normalized to vinculin. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001. Copyright 2022, American Thoracic Society.The image A shows a schematic of the mTORC1/NFkappaB/DPP4 signaling pathway in hypoxia-induced pulmonary hypertension. The image B shows a diagram of nanoscale drug delivery systems for PAH immunotherapy, highlighting various cells and treatments. The image C shows a model of the caspase-8 canonical inflammasome pathway in PAH pathogenesis, with macrophage involvement. The image D shows bar graphs comparing cardiac function metrics (TAPSE, CO, cardiac index, RVSP, PAAT) in PBS, MCT-V and MCT+MCC950 treated rats, indicating significant improvements with MCC950. The image E shows histological assessments of pulmonary arterioles in different treatment groups, with a graph showing reduced medial wall thickness in MCT+MCC950 rats. The image F shows a Western blot assay with graphs indicating lower expression of NLRP3 and cleaved IL-1beta in MCT+MCC950 rats compared to MCT-V, normalized to vinculin.Diagrams and graphs on PAH pathways, treatments and effects in rats. Immunomodulators alleviate PAH by reducing the secretion of inflammatory cytokines. (A) Schematic diagram showing activation of the mTORC1/NFκB/DPP4 signaling pathway in hypoxia-induced PH. Copyright 2019, Springer. (B) Nanoscale drug delivery systems for PAH immunotherapy. Copyright 2021, Elsevier. (C) Model of the caspase-8 canonical inflammasome pathway in the pathogenesis of PAH. Copyright 2022, Williams and Wilkins. (D) Cardiac function was improved in the MCT-MCC950 group by treatment with the NLRP3 inhibitor MCC950, as compared to rats treated with the vehicle (MCT-V) (n =8 phosphate-buffered saline, 8 MCT-V, and 11 MCT-MCC950), as demonstrated by increased tricuspid annular plane systolic excursion (P = 0.016), cardiac output (P = 0.042), and cardiac index (P = 0.025). There was also a significant improvement in systolic pressure of the RV (P = 0.043) and pulmonary artery acceleration time (P = 0.022). (E) Histological assessment of the pulmonary arterioles by staining with hematoxylin and eosin (n = 3 rats/group; > 20 arterioles/rat). MCC950 treatment reduced the percent median wall thickness of the pulmonary arteries in MCT rats as compared to controls (P < 0.0001 comparing rats or arterioles). Scale bars, 20 μm. (F) Western blot assay showing significantly lower expression of NLRP3 (P = 0.035) and cleaved IL-1β (P = 0.0082) in the RVs of MCT rats treated with MCC950 as compared to the vehicle only group (n = 5 phosphate-buffered saline, 6 MCT-V, and 7 MCT-MCC950 rats). The content of target proteins was normalized to vinculin. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001. Copyright 2022, American Thoracic Society. Antibody-Based Biologics Elevated levels of inflammatory cytokines produced by immune and vascular cells in PAH exacerbate injury to the pulmonary vasculature, establishing a positive feedback loop that further propagates disease progression.13,26 Tocilizumab, a well-established IL-6 receptor antagonist with demonstrated safety and efficacy profiles, has garnered substantial preclinical evidence supporting the blockade of IL-6 signaling as a viable therapeutic approach for PAH. Clinical investigations have substantiated the feasibility of tocilizumab for treatment of PAH. However, the hemodynamic parameters of individuals with heritable or idiopathic PAH remained statistically unaltered following intervention.27 Tumor necrosis factor-alpha antagonists attenuate the inflammatory responses of pulmonary tissues, reduce pulmonary arterial pressure, and suppress pulmonary vascular remodeling, thereby ameliorating the initiation and progression of PAH.28 Antioxidant Therapeutics ROS are predominantly generated by aberrantly activated NADPH oxidases and dysfunctional mitochondria within the vasculature, thereby eliciting OS and consequent oxidative damage to proteins, lipids, and DNA.29 Intracellular ROS homeostasis is precisely modulated through the equilibrium between ROS-generating enzymes and antioxidant enzymes, the latter of which are positively regulated by the transcription factor nuclear factor erythroid 2-related factor 2.30 Experimental studies have demonstrated that activation of the 5-hydroxytryptamine 1B receptor upregulates expression of NADPH oxidase 1, thereby inducing OS and impairing functionality of nuclear factor erythroid 2-related factor 2, ultimately culminating in injury to the pulmonary vasculature.31 Given that damaged mitochondria are the principal source of excessive ROS production, the β3-adrenergic receptor agonist mirabegron has been shown to ameliorate mitochondrial dynamics via modulation of dynamin-related protein 1 phosphorylation, thereby conferring protection against hypoxia-induced ROS accumulation and mitochondrial fragmentation in PAECs.32 Folic acid and 4-phenylbutyric acid can reverse eNOS uncoupling and inhibit endoplasmic reticulum stress, thereby blocking the OS cascade, improving hypoxia- and 2,4-diamino-6-hydroxypyrimidine-induced elevation of ROS production and mitochondrial dysfunction, and protecting PAECs.33 Epigallocatechin gallate/manganese dioxide core‑shell nanoparticles (NPs) ameliorate OS and pulmonary vascular remodeling by scavenging ROS and reactive nitrogen species, inhibiting pathological proliferation of PASMCs, restoring inflammatory balance, and suppressing excessive immune activation, thus protecting against PAH.34 Low-Molecular-Weight Pharmacological Agents Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal anti-inflammatory drugs exert anti-inflammatory effects through inhibition of cyclooxygenase-2 enzymatic activity, which attenuates prostacyclin biosynthesis and modulates vascular homeostasis.35 Aspirin, a non-selective inhibitor of cyclooxygenase-2 widely employed for anti-inflammatory and antiplatelet aggregation indications, has been demonstrated to significantly attenuate monocrotaline (MCT)-induced PAH in experimental rat models via suppression of the extracellular signal-regulated kinase/mitogen-activated protein kinase signaling cascade.36 Polyphenolic Compounds Resveratrol, a naturally occurring polyphenolic compound, exhibits potent antioxidant, cardioprotective, and anti-inflammatory properties, effectively suppressing proliferation of PASMCs and attenuating remodeling of the RV.37 Additionally, resveratrol activates eNOS signaling, thereby markedly diminishing ROS generation within the vascular compartment, alleviating OS, and ameliorating the functional integrity of small PAECs, collectively contributing to PAH prophylaxis.38 Furthermore, structurally diverse polyphenolic agents—including catechins, quercetin, and anthocyanins—exert antiproliferative effects on PASMCs and reverse pulmonary vascular remodeling through distinct molecular mechanisms: enhancement of eNOS expression, modulation of the AKT and extracellular signal-regulated kinase 1/2 signaling pathways, and downregulation of heat shock protein 70.39 Statins Statins attenuate inflammation and OS associated with PAH, suppress proliferation of PASMCs, and upregulate expression of Krüppel-like factor 2 (KLF2)—a critical modulator of pro-inflammatory activation of myeloid cells—as well as genes related to the NO pathway.39,40 Moreover, clinical administration of simvastatin to patients with idiopathic, hereditary, and connective tissue disease-associated PAH has demonstrated therapeutic potential. Mechanistically, simvastatin inhibits lymphocyte functionality and ameliorates remodeling of the RV through KLF2-mediated suppression of NF-κB nuclear translocation, thereby establishing its clinical utility in PAH management.40,41 Flavonoid Compounds Dihydromyricetin, a bioactive flavonoid compound, exhibits potent antioxidant and anti-inflammatory properties.42 Combined therapeutic intervention with dihydromyricetin and sildenafil significantly attenuated the expression levels of chemokine-like factor 1, C-C chemokine receptor type 5, NF-κB, NLRP3, apoptosis-associated speck-like protein containing a CARD, cysteine-aspartic protease-1, N-terminal gasdermin D, IL-18, IL-1β, and tumor necrosis factor-alpha in experimental rodent models of PH. These findings suggest that dihydromyricetin may exert anti-inflammatory and anti-pulmonary arterial remodeling effects, at least in part, through the amelioration of pyroptosis.43 Therefore, relevant researches concerning the targeted nanodelivery of combination drug therapies will be discussed in detail in Nanodelivery of Combination Drug Therapies below. Nanocarrier (NC)-Based Anti-Inflammatory and Antioxidant Therapeutics Advantages of Nanopharmaceuticals The aforementioned pharmacological agents demonstrate favorable anti-inflammatory and antioxidant efficacy, although clinical utility is substantially constrained upon systemic administration by poor aqueous solubility, rapid metabolic clearance, and suboptimal stability, which collectively impede targeted drug liberation at pathological loci, thus necessitating the incorporation of drug delivery vehicles to achieve efficient in vivo release.41,44 The intrinsic physicochemical attributes of nanomaterials—including, but not limited to, dimensions, morphology, uniformity, and surface modifiability—facilitate enhanced biocompatibility, target specificity, and diminished cytotoxicity. Consequently, nanomaterials constitute promising vectors for the targeted delivery of PAH therapeutics to lesions of the pulmonary arteries.44,45 Nanopharmaceuticals can be engineered by selecting diverse NC architectures—such as liposomes, polymeric NPs, and exosomes—tailored to specific pathogenic mediators and the distinctive pulmonary vascular microenvironment characteristic of PAH. Subsequent surface functionalization enables precise targeting of pathological lesions and controlled drug release for optimized therapeutic outcomes.45 As compared to conventional formulations, NC-based drug delivery substantially prolongs pharmacokinetic half-life, enhances physicochemical stability, achieves specific targeting of pulmonary pathological foci, and minimizes systemic adverse effects. Furthermore, localized administration modalities, including nebulized inhalation and intratracheal instillation, facilitate pulmonary drug enrichment while further reducing systemic toxicity.46 In recent years, a plethora of emerging nanotherapeutics targeting inflammatory and OS pathways have demonstrated promising therapeutic efficacy against PAH by enabling pulmonary delivery of nucleic acids or small-molecule agents for highly efficient genetic or pharmacological intervention. Accordingly, we systematically summarize NC-based anti-inflammatories and antioxidants for PAH, which are intuitively illustrated in Scheme 2. Furthermore, we comprehensively sort out core research information of diverse nanocarrier platforms for the delivery of anti-inflammatory and antioxidant agents, including their research stage, major clinical translation challenges, administration routes, therapeutic advantages and main limitations, and summarize the above key contents in Table 1. Scheme 2NC-based anti-inflammatories and antioxidants.A diagram categorizing nanocarriers: liposomes, polymeric nanoparticles, exosomes and other carriers.Table 1Nanocarrier platforms for delivery of anti‑inflammatory and antioxidant agents for the treatment of PAHNanocarrier CategoryNanocarrier NameResearch StageMajor Challenges for Clinical TranslationTherapeutic PayloadAdministration RouteTherapeutic AdvantagesMain LimitationsLiposomal NCsEngineered liposomesPreclinical animal studyAntigen delivery barriers; free CRX-601 carries pyrogenic riskCRX-601SublingualEquivalent systemic immunity to IM injection; produce mucosal IgA; MGC modification raises antibody titerNo proven anti-influenza protective effect; no statistical therapeutic superiority; immune mechanism unclearDPPC-LNsCell & animal studyExcipient dose-dependent toxicity; insufficient toxicology and pharmacology dataResveratrolIntratracheal inhalationSustained release, improved cell uptake, inhibited PASMC proliferation; higher lung drug retentionUnstable at room temperature within 7 days; equal efficacy to free resveratrol; only verified in healthy ratsNanoliposomesCell & animal studyHigh statin doses cause liver injury and rhabdomyolysis; cerivastatin lactone is toxicCerivastatinInhalationLess toxic metabolite production; improved cardiopulmonary function in PAH models, better safetyFree cerivastatin inhibits HPASMC more strongly; efficacy improvement lacks statistical significanceCationic liposomal nanoparticlesIn vitro and ex vivo preclinical studySpecies difference in pulmonary artery receptors; unclear vasodilation mechanism; low encapsulation efficiency (~4%)IloprostNot statedNon-cytotoxic to hPASMC/A549; most formulations boost pulmonary vasorelaxationUncertain efficacy in human vessels; cholesterol reduces drug loading; vasodilatory effect non-significantPolymeric NPsOIL-NPsCell & animal studyCore molecular therapeutic mechanism unclarifiedDescurainia sophia fatty oilIntravenous injectionProtect mitochondria, suppress RPASMC proliferation via PLC/IP3R/Ca2⁺ pathway; superior to free oilDownstream signaling pathway needs further validationMPP nanoparticlesCell & animal studyNo obvious translational obstacles reportedMelanin-based MPPIntravenous injectionTiny particle size, good water solubility, biocompatibility and antioxidant capacityROS/TGF-β1 regulatory mechanism unconfirmedCS–CoO nanocomposite filmsCell studyDifficult synthesis of tiny NPs; improper size may induce embolism; metal oxide impairs bioactivityCoO NPsIn vitro direct exposureElevated antibacterial, antifungal, anti-tumor and antioxidant activity; UV enhances ROS-mediated bioactivityOnly validated in vitro; anti-cancer effect partially UV-dependent; exact mechanism unknownExosomesMSC-ExosAnimal studyImpure separation; FBS-derived EV contamination; ambiguous miRNA regulatory pathwayEndogenous miRNA cargoTail vein intravenous injectionAlleviate MCT-induced PAH and RV hypertrophy; human and mouse MSC exosomes have equal efficacyLack unified isolation standard; causal link between miRNA and PAH unprovenMSC-tadalafil-ExosCell & animal studyHeterogeneous exosome components; inadequate clinical safety evidencemiR-29a-3pTail vein intravenous injectionHigher therapeutic miRNA content; low immunogenicity, no teratoma riskPoor uptake by pulmonary SMCs; cannot block hypoxic SMC malignant transformation; universal vascular applicability unknownKLF2-induced endothelial exosomesCell & animal studyViral impurities in purified exosomes; unknown miRNA sorting mechanismmiR-181a-5p + miR-324-5pIntravenous injectionInhibit vascular proliferation and angiogenesis; slow PAH progression in miceLow yield restricts clinical translation; KLF2-mediated miRNA upregulation mechanism unclearRBP-exo/CurCell & animal studyLow exosome yield and loading efficiency; complicated quality controlRAGE-binding peptide + CurcuminIntratracheal instillationRBP exerts anti-inflammation; enhanced pulmonary curcumin delivery; relieve lung inflammationHigh-dose exosomes trigger immune response; heterogeneous protein components; pleiotropic effects unelaboratedExo-ITGB1Cell & animal studyIncomplete PAH therapeutic mechanism elucidationmiR-429-3pIntratracheal instillationProtect miRNA from RNase degradation; target lung cells; reverse remodeling via miR-429-3p/Rac1 axisPAH curative effect needs more verification; Rac1 overexpression counteracts PASMC inhibitionOther CarriersGA-BNRplexCell & animal studyUncertain rapid relief after single dose; NP mechanical property effects unstudiedBaicalein + p53 plasmid DNAIntravenous injectionHigh payload capacity; GLUT-1 targeted PASMC delivery; caveola-mediated nuclear transfection avoiding lysosomal degradationOnly effective in MCT-PAH model; untested in hypoxia/bleomycin-induced PAHCAR-modified lipid mixtureAnimal studyUnknown corrosiveness of DETA NONOate; unevaluated long-term safetyFasudil + DETA NONOateIntratracheal administrationSelectively lower mPAP without systemic hypotension; improve hemodynamics, RV function and pulmonary pathologyNo improvement in microvessels <100 μm; long-term toxicity unclear; synergistic mechanism uncharacterizedBilosomesAnimal studyHard large-scale production; unapproved for pediatric useSildenafil citrate (SDF)Transdermal topical administrationHigh encapsulation efficiency; flexible vesicles improve skin penetration; 2.34-fold higher transdermal permeationPoor storage stability; sildenafil disallowed for children by FDAABI-009 (nab-Sirolimus)Phase I clinical trial10 mg/m2 dose intolerable for PAH patientsSirolimusIntravenous infusionElevate WHO functional class; extend walking distance for partial patientsSingle-arm open-label trial without definitive efficacy confirmation; narrow safe dosage rangeAZM-AgNPsAnimal studyEfficacy and safety require more clinical verificationAzithromycinTopical wound applicationPotent anti-MRSA/E. coli activity, lower MIC; accelerate wound contraction, granulation and collagen depositionOnly tested in short-term in vitro assays and small rat wound models; lacking clinical trial data NC-based anti-inflammatories and antioxidants. Table 1Nanocarrier platforms for delivery of anti‑inflammatory and antioxidant agents for the treatment of PAHNanocarrier CategoryNanocarrier NameResearch StageMajor Challenges for Clinical TranslationTherapeutic PayloadAdministration RouteTherapeutic AdvantagesMain LimitationsLiposomal NCsEngineered liposomesPreclinical animal studyAntigen delivery barriers; free CRX-601 carries pyrogenic riskCRX-601SublingualEquivalent systemic immunity to IM injection; produce mucosal IgA; MGC modification raises antibody titerNo proven anti-influenza protective effect; no statistical therapeutic superiority; immune mechanism unclearDPPC-LNsCell & animal studyExcipient dose-dependent toxicity; insufficient toxicology and pharmacology dataResveratrolIntratracheal inhalationSustained release, improved cell uptake, inhibited PASMC proliferation; higher lung drug retentionUnstable at room temperature within 7 days; equal efficacy to free resveratrol; only verified in healthy ratsNanoliposomesCell & animal studyHigh statin doses cause liver injury and rhabdomyolysis; cerivastatin lactone is toxicCerivastatinInhalationLess toxic metabolite production; improved cardiopulmonary function in PAH models, better safetyFree cerivastatin inhibits HPASMC more strongly; efficacy improvement lacks statistical significanceCationic liposomal nanoparticlesIn vitro and ex vivo preclinical studySpecies difference in pulmonary artery receptors; unclear vasodilation mechanism; low encapsulation efficiency (~4%)IloprostNot statedNon-cytotoxic to hPASMC/A549; most formulations boost pulmonary vasorelaxationUncertain efficacy in human vessels; cholesterol reduces drug loading; vasodilatory effect non-significantPolymeric NPsOIL-NPsCell & animal studyCore molecular therapeutic mechanism unclarifiedDescurainia sophia fatty oilIntravenous injectionProtect mitochondria, suppress RPASMC proliferation via PLC/IP3R/Ca2⁺ pathway; superior to free oilDownstream signaling pathway needs further validationMPP nanoparticlesCell & animal studyNo obvious translational obstacles reportedMelanin-based MPPIntravenous injectionTiny particle size, good water solubility, biocompatibility and antioxidant capacityROS/TGF-β1 regulatory mechanism unconfirmedCS–CoO nanocomposite filmsCell studyDifficult synthesis of tiny NPs; improper size may induce embolism; metal oxide impairs bioactivityCoO NPsIn vitro direct exposureElevated antibacterial, antifungal, anti-tumor and antioxidant activity; UV enhances ROS-mediated bioactivityOnly validated in vitro; anti-cancer effect partially UV-dependent; exact mechanism unknownExosomesMSC-ExosAnimal studyImpure separation; FBS-derived EV contamination; ambiguous miRNA regulatory pathwayEndogenous miRNA cargoTail vein intravenous injectionAlleviate MCT-induced PAH and RV hypertrophy; human and mouse MSC exosomes have equal efficacyLack unified isolation standard; causal link between miRNA and PAH unprovenMSC-tadalafil-ExosCell & animal studyHeterogeneous exosome components; inadequate clinical safety evidencemiR-29a-3pTail vein intravenous injectionHigher therapeutic miRNA content; low immunogenicity, no teratoma riskPoor uptake by pulmonary SMCs; cannot block hypoxic SMC malignant transformation; universal vascular applicability unknownKLF2-induced endothelial exosomesCell & animal studyViral impurities in purified exosomes; unknown miRNA sorting mechanismmiR-181a-5p + miR-324-5pIntravenous injectionInhibit vascular proliferation and angiogenesis; slow PAH progression in miceLow yield restricts clinical translation; KLF2-mediated miRNA upregulation mechanism unclearRBP-exo/CurCell & animal studyLow exosome yield and loading efficiency; complicated quality controlRAGE-binding peptide + CurcuminIntratracheal instillationRBP exerts anti-inflammation; enhanced pulmonary curcumin delivery; relieve lung inflammationHigh-dose exosomes trigger immune response; heterogeneous protein components; pleiotropic effects unelaboratedExo-ITGB1Cell & animal studyIncomplete PAH therapeutic mechanism elucidationmiR-429-3pIntratracheal instillationProtect miRNA from RNase degradation; target lung cells; reverse remodeling via miR-429-3p/Rac1 axisPAH curative effect needs more verification; Rac1 overexpression counteracts PASMC inhibitionOther CarriersGA-BNRplexCell & animal studyUncertain rapid relief after single dose; NP mechanical property effects unstudiedBaicalein + p53 plasmid DNAIntravenous injectionHigh payload capacity; GLUT-1 targeted PASMC delivery; caveola-mediated nuclear transfection avoiding lysosomal degradationOnly effective in MCT-PAH model; untested in hypoxia/bleomycin-induced PAHCAR-modified lipid mixtureAnimal studyUnknown corrosiveness of DETA NONOate; unevaluated long-term safetyFasudil + DETA NONOateIntratracheal administrationSelectively lower mPAP without systemic hypotension; improve hemodynamics, RV function and pulmonary pathologyNo improvement in microvessels <100 μm; long-term toxicity unclear; synergistic mechanism uncharacterizedBilosomesAnimal studyHard large-scale production; unapproved for pediatric useSildenafil citrate (SDF)Transdermal topical administrationHigh encapsulation efficiency; flexible vesicles improve skin penetration; 2.34-fold higher transdermal permeationPoor storage stability; sildenafil disallowed for children by FDAABI-009 (nab-Sirolimus)Phase I clinical trial10 mg/m2 dose intolerable for PAH patientsSirolimusIntravenous infusionElevate WHO functional class; extend walking distance for partial patientsSingle-arm open-label trial without definitive efficacy confirmation; narrow safe dosage rangeAZM-AgNPsAnimal studyEfficacy and safety require more clinical verificationAzithromycinTopical wound applicationPotent anti-MRSA/E. coli activity, lower MIC; accelerate wound contraction, granulation and collagen depositionOnly tested in short-term in vitro assays and small rat wound models; lacking clinical trial data Nanocarrier platforms for delivery of anti‑inflammatory and antioxidant agents for the treatment of PAH NC Platforms for Delivery of Anti-Inflammatories and Antioxidants Liposomal NCs Liposomes are self-assembled vesicles composed of phospholipids or lipid analogs and related derivatives, characterized by a distinctive bilayer architecture that confers both hydrophilic and hydrophobic properties. The aqueous core of these vesicular structures accommodates hydrophilic therapeutic agents, whereas the interstitial region of the lipid bilayer serves as a reservoir for incorporation of hydrophobic drugs (Figure 2A).47 Based on the surface charge, liposomes are classified as neutral, anionic, or cationic formulations.48 The bilayer structural configuration of liposomal carriers exhibits enhanced permeability across biological barriers. Pulmonary administration utilizing liposomal platforms effectively reduces dosing frequency and minimizes extrapulmonary drug deposition, thereby facilitating sustained drug release and targeted delivery to specific pulmonary loci.49 Figure 2Liposome-mediated drug delivery for PAH treatment. (A) Liposome structure schematic showing a spherical vesicle with an aqueous core formed by a phospholipid and cholesterol bilayer. The liposome aqueous core can encapsulate hydrophilic drugs whereas hydrophobic drugs reside in the lipid bilayer. Copyright 2018, Elsevier. (B) Structure of DPPC. Copyright 2018, Elsevier. (C) Physicochemical stability of resveratrol-DPPC-LNs: entrapment efficiency, polydispersity index, size, and zeta potential. Data are presented as the mean ± standard deviation (SD), n = 3. (D) In vivo absorption profile and the lung concentration-time profiles of resveratrol following intratracheal inhalation of resveratrol-DPPC-LNs and intravenous administration of resveratrol solution to rats (dose = 10 mg/kg, mean ± SD, n = 6). ***P < 0.001. Copyright 2020, Taylor and Francis. (E and F) Characterization of cerivastatin liposomes. Representative negatively stained images of cerivastatin-loaded liposomes by transmission electron microscopy at original magnification, 5000×, and 20,000×. The number and average hydrodynamic radius of cerivastatin-loaded liposomes as determined by dynamic light scattering. The release kinetics were investigated using the dialysis method (molecular weight cut-off, 3500 Da) under sink conditions. (G) Effect of free and liposomal cerivastatin on smooth muscle cell proliferation and cytotoxicity. Human pulmonary artery smooth muscle cells plated at a density of 50,000 cells per well, in triplicate, in 24-well plates. The cells were then treated with the indicated concentrations of free cerivastatin (black bar), liposome cerivastatin (gray bar), or growth medium (control) for 48 h. **P < 0.01 and ***P < 0.001 for control versus different dose with CV. #P < 0.05, ##P < 0.01, ###P < 0.001 for CV versus LP within same dose. Copyright 2018, Elsevier.Image A depicts a liposome with components: HSPC, cholesterol, hydrophilic/hydrophobic drugs, PEG coating and intraliposomal drug precipitate. Image B shows DPPC′s chemical structure. Image C features bar charts over time (0, 1, 2, 3, 7, 14, 30 days): EE percent stays 90-100; PDI rises from 0.06 to 0.11; Z-average is 110-130 nm; Zeta Potential decreases from 18 to 6 mV at 4 degrees C and 25 degrees C. Image D has a line graph comparing Res-DPPC-LNs I. T. and Res solution I. V. over 0-720 min, with an inset for 0-90 min and a bar chart showing concentration over time (5, 30, 60, 120, 240, 720 min) with early time points highlighted. Image E shows TEM images of cerivastatin-loaded liposomes. Image F includes a size distribution histogram and a line graph of cerivastatin release reaching 70% by 200 hours. Image G presents bar charts of cell count and viability versus cerivastatin concentration (Control, 0.01, 0.03, 0.1, 0.3, 1 microM), with decreasing cell numbers and viability, marked with symbols.Infographic on liposome drug delivery: DPPC structure, stability, absorption, size, release and cell response. Liposome-mediated drug delivery for PAH treatment. (A) Liposome structure schematic showing a spherical vesicle with an aqueous core formed by a phospholipid and cholesterol bilayer. The liposome aqueous core can encapsulate hydrophilic drugs whereas hydrophobic drugs reside in the lipid bilayer. Copyright 2018, Elsevier. (B) Structure of DPPC. Copyright 2018, Elsevier. (C) Physicochemical stability of resveratrol-DPPC-LNs: entrapment efficiency, polydispersity index, size, and zeta potential. Data are presented as the mean ± standard deviation (SD), n = 3. (D) In vivo absorption profile and the lung concentration-time profiles of resveratrol following intratracheal inhalation of resveratrol-DPPC-LNs and intravenous administration of resveratrol solution to rats (dose = 10 mg/kg, mean ± SD, n = 6). ***P < 0.001. Copyright 2020, Taylor and Francis. (E and F) Characterization of cerivastatin liposomes. Representative negatively stained images of cerivastatin-loaded liposomes by transmission electron microscopy at original magnification, 5000×, and 20,000×. The number and average hydrodynamic radius of cerivastatin-loaded liposomes as determined by dynamic light scattering. The release kinetics were investigated using the dialysis method (molecular weight cut-off, 3500 Da) under sink conditions. (G) Effect of free and liposomal cerivastatin on smooth muscle cell proliferation and cytotoxicity. Human pulmonary artery smooth muscle cells plated at a density of 50,000 cells per well, in triplicate, in 24-well plates. The cells were then treated with the indicated concentrations of free cerivastatin (black bar), liposome cerivastatin (gray bar), or growth medium (control) for 48 h. **P < 0.01 and ***P < 0.001 for control versus different dose with CV. #P < 0.05, ##P < 0.01, ###P < 0.001 for CV versus LP within same dose. Copyright 2018, Elsevier. The primary constituent of liposomal membrane materials comprises phospholipids, among which 1,2-dipalmitoylphosphatidylcholine (DPPC; systematic nomenclature: 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine) represents a prototypical neutral phospholipid exhibiting favorable biocompatibility and is frequently employed as a liposomal excipient for encapsulating chemotherapeutic agents (Figure 2B).50 Pulmonary-specific mucus barrier penetration, alveolar macrophage-mediated phagocytic clearance, and pulmonary surfactant-induced modulation of nanoparticle stability collectively serve as the core determinants governing the delivery efficacy and therapeutic success of inhaled nanoformulations. Resveratrol suffers from poor water solubility, rapid metabolic clearance following oral administration, low systemic bioavailability and short pulmonary retention time, which severely restricts its clinical application. Encapsulating resveratrol into DPPC-coated lipid nanoparticles for pulmonary delivery can improve drug solubility and loading capacity via nanotechnology, bypass hepatic first-pass metabolism, achieve sustained drug release, reduce nanoparticle clearance by pulmonary macrophages, and enhance uptake by pulmonary arterial smooth muscle cells. DPPC-based lipid NPs (DPPC-LNs) have been extensively investigated as vehicles for delivery of resveratrol in PAH therapeutics. Resveratrol-loaded DPPC-LNs fabricated by Li et al,51 demonstrated robust biocompatibility and structural stability, capable of protecting the encapsulated resveratrol from enzymatic degradation and modulating its release kinetics (Figure 2C and D). Concurrently, DPPC effectively circumvents the pharmacokinetic limitations and poor aqueous solubility inherent to resveratrol, thereby substantially enhancing systemic bioavailability. Lee et al (Figure 2E–G)52 developed cerivastatin-loaded liposomes formulated with DPPC and cholesterol. In vitro investigations demonstrated that, as compared to free cerivastatin, the liposomal formulation markedly suppressed proliferation of PASMCs, while exhibiting attenuated cytotoxicity. Cationic liposomes, by virtue of a positive surface charge, can electrostatically interact with negatively charged nucleic acids or therapeutic agents. For instance, cationic liposomes encapsulate the anionic prostacyclin analog iloprost through electrostatic interactions, achieving an encapsulation efficiency of approximately 50%.53 Simvastatin is highly hydrophobic with poor aqueous solubility, and systemic administration suffers from first-pass metabolism, insufficient gastrointestinal absorption and off-target distribution. Spray-dried inhalable solid prolipid nano/microparticles composed of pulmonary surfactant-mimetic DPPC/DPPG can hydrate into multilamellar liposomes in the lung, encapsulating simvastatin within lipid bilayers to enable direct pulmonary delivery, sustained release, deep lung deposition and improved storage stability.54 Most of the aforementioned nanocarriers achieve passive accumulation and retention at lesion sites via the EPR effect and particle size advantages. Alternatively, ligand modification can be adopted to specifically bind receptors overexpressed on diseased endothelial cells in PAH, thereby realizing precise active targeted delivery. Cao et al constructed three-component LNPs centered on ionizable A5-3O14 lipids to intravenously deliver BMPR2 mRNA to pulmonary vascular endothelial cells. These LNPs effectively restore the BMPR2 and downstream SMAD1/5/9-ID1 signaling pathways and reverse cardiopulmonary pathological lesions in PAH models, verifying that such endothelium-selective LNPs can target and correct key molecular defects underlying PAH.55 Compared with passive targeting relying on vascular permeability and particle size, ligand modification enables nanocarriers to actively recognize lesional endothelial cells in PAH. Engineered extracellular vesicles loaded with Apelin-13 are surface-functionalized with the PAH-homing peptide CARSKNKDC, which binds to heparan sulfate overexpressed on diseased endothelial cells to strengthen selective accumulation in PAH-injured pulmonary blood vessels. This formulation improves the in vivo stability and lesion-specific distribution of Apelin-13, reduces right ventricular systolic pressure and right ventricular hypertrophy, and reverses pulmonary vascular remodeling, verifying that ligand modification targeting surface molecules on lesional endothelium serves as an effective strategy to enhance the targeting selectivity of nanotherapy for PAH.56 Despite extensive utilization of liposomes as drug delivery platforms, inherent limitations persist, including potential drug-associated cytotoxicity and generally suboptimal drug loading efficiencies. Consequently, nanostructured lipid carriers developed to ameliorate these deficiencies exhibit favorable biodegradability and an acceptable safety profile, concomitantly prolonging pulmonary drug exposure. Intratracheal instillation of nanostructured lipid carriers not only attenuates arterial remodeling but also suppresses pro-inflammatory cytokine production, thereby diminishing pulmonary vascular resistance. Polymeric NPs Polymeric NPs are constructed from natural or synthetic materials as monomers with physicochemical properties that can be precisely modulated through functionalization to achieve targeted drug delivery and barrier penetration (Figure 3A).57 Nanocapsules and nanospheres are the two most prevalent categories of polymeric NPs. The former encapsulates drugs within a polymer-formed cavity (Figure 3B),58 whereas the latter disperses drugs physically throughout a solid polymeric matrix. By adjusting the composition, architecture, dimensions, stability, and performance of polymeric nanomaterials, these systems can protect drugs from chemical degradation and enable targeted transport along with controlled release.59 Figure 3NP-mediated drug delivery for PAH treatment. (A) Illustration of polymeric nanomedicines targeting hematological malignancies mediated by specific ligand-receptor interactions. Copyright 2021 Elsevier. (B) Schematic diagrams of various drug-loaded polymersome structures. Copyright 2020, 2022 Elsevier, 2014 Wiley, 2015, 2020 American Chemical Society. (C–E) Effects of OIL-NPs on echocardiographic features, pulmonary artery pressure, and pathological lung injury of PH rats. Staining with Masson trichrome and hematoxylin and eosin (magnification, ×400). Black arrows point to the pulmonary vascular portion. **P < 0.01 vs the NC group. ##P < 0.01 vs the M group. &&P < 0.01 vs the OIL-H group. Copyright 2023, Taylor and Francis. (F) Schematic illustration of NPs loaded with MPP for treatment of PH. NPs loaded with MPP administrated to rats with MCT-induced PH reduced MCT-induced proliferation and migration of PASMCs and attenuated pulmonary vascular remodeling via inhibition of the ROS/transforming growth factor-β1 pathway. Copyright 2024, Wiley.The composite image consists of six parts. A shows actively targeted nanomedicines interacting with hematological malignancies, highlighting receptors like mAb, protein, aptamer, peptide, polymer and small molecule. B illustrates various drug-loaded polymersome structures. C displays echocardiographic images with labels. D is a bar graph of mPAP in mmHg, comparing NC, M, OIL-L, OIL-H, OIL-PLGA-L, OIL-PLGA-H and PLC groups, with significant differences marked. E shows lung histology images stained with Masson trichrome and hematoxylin and eosin, with black arrows indicating pulmonary vascular portions. F illustrates the treatment of PH in rats using NPs loaded with MPP, showing the inhibition of the ROS/transforming growth factor-beta 1 pathway, reducing proliferation and migration of PASMCs and attenuating pulmonary vascular remodeling. The diagram contrasts untreated and MPP-treated PH rats, detailing molecular interactions and effects on PASMCs.Nanomedicine targeting: polymersomes, echocardiography, mPAP graph, lung histology, PH treatment. NP-mediated drug delivery for PAH treatment. (A) Illustration of polymeric nanomedicines targeting hematological malignancies mediated by specific ligand-receptor interactions. Copyright 2021 Elsevier. (B) Schematic diagrams of various drug-loaded polymersome structures. Copyright 2020, 2022 Elsevier, 2014 Wiley, 2015, 2020 American Chemical Society. (C–E) Effects of OIL-NPs on echocardiographic features, pulmonary artery pressure, and pathological lung injury of PH rats. Staining with Masson trichrome and hematoxylin and eosin (magnification, ×400). Black arrows point to the pulmonary vascular portion. **P < 0.01 vs the NC group. ##P < 0.01 vs the M group. &&P < 0.01 vs the OIL-H group. Copyright 2023, Taylor and Francis. (F) Schematic illustration of NPs loaded with MPP for treatment of PH. NPs loaded with MPP administrated to rats with MCT-induced PH reduced MCT-induced proliferation and migration of PASMCs and attenuated pulmonary vascular remodeling via inhibition of the ROS/transforming growth factor-β1 pathway. Copyright 2024, Wiley. Solid polymeric NPs are typically assembled from macromolecular polymers, with size dimensions ranging from the nanometer to micrometer scale, and are frequently employed for the delivery of both hydrophilic and hydrophobic therapeutic agents. Among these, poly(lactic-co-glycolic acid) (PLGA) has emerged as one of the most extensively investigated polymeric NPs owing to excellent biocompatibility and biodegradability, with PLGA-based NPs being widely utilized in pulmonary drug delivery systems.60 Bashal et al fabricated chitosan-cobalt(II) oxide (CS–CoO) nanocomposite films. Cobalt oxide nanoparticles can be incorporated into the chitosan matrix and modulate its crystalline structure and surface morphology. Increasing the CoO loading from 5 wt% to 20 wt% reduces the crystallite size and enhances the antibacterial, antifungal, anticancer and antioxidant activities of the composites.61 In the context of PAH therapeutics, Zheng et al,62 developed OIL-NPs by encapsulating fatty oils within PLGA-NPs and subsequently conducted both in vitro and in vivo investigations to elucidate the anti-PAH efficacy (Figure 3C–E). In vitro studies demonstrated that OIL-NPs ameliorated mitochondrial function and suppressed the malignant proliferation of PASMCs via inhibition of the PLC/IP3R/Ca2+ signaling pathway. Furthermore, OIL-NPs attenuated pulmonary arterial pressure in rats, ameliorated cardiopulmonary pathological damage, and mitigated inflammatory responses. Beyond PLGA, alternative polymeric NPs have also been applied for treatment of PAH. Rapamycin suffers from poor water solubility and triggers systemic adverse reactions such as weight loss and elevated pro-inflammatory cytokines when administered in free form. PEG-PCL nanoparticles can solubilize and encapsulate rapamycin, which preferentially accumulates in lesional pulmonary vessels of PAH patients after intravenous injection. Compared with free rapamycin, this nanoformulation achieves comparable therapeutic efficacy while alleviating weight loss and inflammatory responses and reducing systemic side effects.63 MPC polymer timed-release nanocapsules encapsulating rituximab (n-RTX) overcome the drawbacks of free rituximab including poor blood-brain barrier penetration and insufficient, short-duration drug exposure in lymph nodes; relying on choline receptor-mediated transcytosis, anti-protein adsorption and hydrolyzable crosslinking structure, the nanoformulation boosts brain and lymph node drug accumulation with sustained release, elevates drug levels in central nervous system and lymphatic tissues and improves lymph node B-cell depletion compared with free rituximab, while causing no obvious acute hepatic or neurotoxicity.64 Liu et al (Figure 3F)65 synthesized NPs with the non-metallic nanozyme melanin-polyvinylpyrrolidone-polyethylene glycol (MPP), which effectively alleviated PAH and associated cardiovascular injuries in rats through suppression of ROS-driven activation of transforming growth factor-β1, while exhibiting favorable in vivo safety profiles. Exosomes Exosomes are a class of nanoscale extracellular vesicles secreted by diverse cell types that play pivotal roles in intercellular communication by facilitating the intercellular transfer of biomolecules, thereby enabling the exchange of information and functional substances. These vesicles exhibit substantial heterogeneity contingent upon parental cell conditions, with distinct exosome subpopulations executing varied biological functions, as novel therapeutic avenues for PAH intervention.66 Exosomes derived from mesenchymal stem cells (MSCs) can attenuate vascular remodeling through modulation of NF-κB signaling or the Wnt5a/BMP signaling pathway. Exosomes secreted by pharmacologically treated or molecularly engineered MSCs frequently demonstrate superior therapeutic efficacy in diverse applications. Exosomes derived from tadalafil-preconditioned bone marrow MSCs (MSC-tadalafil-Exos) constitute a promising exosomal source for PH therapeutics (Figure 4A–D).67 Preconditioning with tadalafil significantly enhanced the anti-inflammatory capacity of MSC-derived exosomes (MSC-Exos) and suppressed serum-deprivation-induced apoptosis of endothelial cells, thereby attenuating hypoxia-driven migration and ultimately diminishing the pro-proliferative and pro-migratory effects of endothelial cells on smooth muscle cells under hypoxic conditions. Sindi et al,68 investigated whether exosomal microRNAs released from KLF2-overexpressing PAECs exert vasoprotective effects in PAH. The findings demonstrated that KLF2 signaling is dysregulated in PAH, with KLF2 actively promoting selective packaging of miR-181a-5p and miR-324-5p into exosomes. KLF2-induced endothelial exosomal microRNAs were found to recapitulate the homeostatic effects of endothelial KLF2 overexpression and laminar shear stress. Exosomes from KLF2-overexpressing PAECs enhanced PAEC survival, attenuated inflammatory responses, and restricted vascular cell proliferation, suggesting potential therapeutic utility against PAH and other pathologies characterized by endothelial injury, inflammation, proliferation, and vascular cell hypertrophy. Figure 4Modified exosomes alleviate PAH through anti-inflammatory effects. (A) Therapeutic mechanism of MSC-Exos for treatment of PAH. (B and C) Cup-shaped morphology of purified MSC-Exos and MSC-tadalafil-Exos (arrowhead), as assessed by transmission electron microscopy. (D) Systolic pressure of the RV was measured by right-sided heart catheterization with a pressure transducer microcatheter. ****P < 0.0001 vs Control. ###P < 0.001, vs Serum-free group. Downwards arrows (↓) represent decrease or attenuation. Copyright 2024, Taylor and Francis. (E) Model illustrating exosomes derived from ITGB1-modified telocytes (Exo-ITGB1) protect against hypoxia-induced PAH. (F and G) Micrographs of exosomes by transmission electron microscopy. Scale bar, 200 nm. (H) Systolic pressure of the RV among groups. **P < 0.01 vs normal group. #P < 0.05, Exo-Ve vs Exo-ITGB1. Copyright 2024, Springer.A composite scientific figure demonstrating that modified exosomes reduce right ventricular systolic pressure in pulmonary arterial hypertension models. Image A is a schematic showing mesenchymal stem cells releasing exosomes carrying miR-29a-3p, which act on macrophages, endothelial cells and smooth muscle cells to reduce inflammation, apoptosis, migration and proliferation. Tadalafil and exosome types are labeled. Images B and C are transmission electron micrographs showing vesicle-like exosome particles, with arrowheads indicating cup-shaped morphology. Scale bar is 200 nanometers. Image D is a bar graph with groups on the x-axis and right ventricular systolic pressure in millimeters of mercury on the y-axis. The SuHx group shows elevated pressure near 40 millimeters of mercury compared to Control near 22. SuHx plus MSC-Exo and SuHx plus MSC-tadalafil-Exo groups show reduced pressure, with significant differences marked. Image E is a schematic showing ITGB1-modified telocyte-derived exosomes delivering miR-429-3p to pulmonary artery smooth muscle cells under hypoxia, leading to vascular remodeling. Images F and G are micrographs of Exo-Ve and Exo-ITGB1 exosomes respectively. Image H is a bar graph where PAH and Exo-Ve groups show elevated right ventricular systolic pressure near 60 millimeters of mercury versus Normal near 25, while Exo-ITGB1 shows a significant reduction near 40 millimeters of mercury.Exosome treatments lower RV systolic pressure in pulmonary hypertension models via diagrams and graphs. Modified exosomes alleviate PAH through anti-inflammatory effects. (A) Therapeutic mechanism of MSC-Exos for treatment of PAH. (B and C) Cup-shaped morphology of purified MSC-Exos and MSC-tadalafil-Exos (arrowhead), as assessed by transmission electron microscopy. (D) Systolic pressure of the RV was measured by right-sided heart catheterization with a pressure transducer microcatheter. ****P < 0.0001 vs Control. ###P < 0.001, vs Serum-free group. Downwards arrows (↓) represent decrease or attenuation. Copyright 2024, Taylor and Francis. (E) Model illustrating exosomes derived from ITGB1-modified telocytes (Exo-ITGB1) protect against hypoxia-induced PAH. (F and G) Micrographs of exosomes by transmission electron microscopy. Scale bar, 200 nm. (H) Systolic pressure of the RV among groups. **P < 0.01 vs normal group. #P < 0.05, Exo-Ve vs Exo-ITGB1. Copyright 2024, Springer. An anti-inflammatory receptor for advanced glycation end-products binding peptide (RBP) was engineered for pulmonary delivery via exosomal encapsulation. This was achieved by fusing RBP to the exosomal membrane integrin protein Lamp2b, generating RBP-conjugated exosomes (RBP-exo), which were subsequently loaded with curcumin. The curcumin-loaded RBP-exo (RBP-exo/Cur) demonstrated substantially enhanced intracellular curcumin delivery efficiency as compared to free curcumin or loaded unmodified exosomes (unmod-exo/Cur).69 Additionally, integrin subunit beta 1-modified platelet-derived exosomes exerted anti-inflammatory effects and reversed vascular remodeling through modulation of the miR-429-3p/Rac1 axis (Figure 4E–H),70 effectively ameliorating the pathophysiology of PAH. Other Carriers Teng et al,71 complexed nuclear localization signal peptides with p53 plasmid DNA (pDNA/pEGFP), which were subsequently co-assembled with baicalein to generate rod-shaped baicalein nanocrystals, designated as baicalein nanorods, for specific co-delivery of the pro-apoptotic executioner gene p53 and the anti-inflammatory agent baicalein to PASMCs to attenuate the pathogenesis of PAH. Furthermore, Zhao et al,72 developed a novel nanocluster formulation (cerium dioxide/bovine serum albumin) capable of efficiently scavenging elevated ROS levels within the pulmonary arteries to ameliorate pulmonary vascular remodeling, reduce pulmonary arterial pressure, and ultimately confer significant cardioprotective effects, thus offering an innovative therapeutic strategy for ROS-targeted PAH intervention. As one of the few nanomedicines entering clinical trials for PAH, ABI-009 is albumin-bound sirolimus nanoparticles that suppress excessive pulmonary vascular proliferation via mTOR inhibition rather than vasodilation. Its Phase I trial on severe treatment-refractory PAH achieves improvements in cardiac function, exercise capacity and pulmonary vascular resistance with acceptable safety, laying groundwork for further clinical translation of nanotherapy for PAH.73 Additionally, Tanoy et al achieved efficient co-encapsulation and pulmonary-targeted delivery of fasudil and DETA-NONOate utilizing CAR peptide-functionalized micelle/nanogel carriers.74 Saddik et al developed a novel pharmaceutical material, azithromycin-loaded silver nanoparticles (AZM-AgNPs), to accelerate wound healing and inhibit bacterial proliferation.75 Bjad et al developed a transdermal gel delivery system based on bile salt-stabilized nanovesicles (bilosomes) to enhance the therapeutic efficacy of sildenafil for pediatric PAH.76 Nanocarrier Safety Although nano-delivery systems possess the aforementioned multiple advantages, their clinical translation is hindered by several safety risks: inherent cytotoxicity of cationic liposomes,77,78 local microenvironmental acidification resulting from PLGA degradation,79 and potential long-term tissue accumulation of high-dose cerium dioxide nanoparticles. These hazards must be fully evaluated and mitigated prior to practical clinical application.80 Optimization Strategies for Nanodelivery Systems Intelligent and Stimuli-Responsive Nanoplatforms Intelligent stimuli-responsive nanodelivery systems represent a class of nanoscale drug delivery platforms endowed with autonomous environmental sensing and adaptive capabilities that enable automatic modulation of drug release in response to specific physiological or pathological conditions (such as pH, temperature, enzymatic activity, or redox status), thereby achieving precise, targeted drug delivery with enhanced therapeutic efficacy and minimized adverse effects. Stimuli-responsive nanomedicine delivery systems have been extensively applied for treatment of neurological disorders.81 Self-immolative DNA nanocapsules,82 polymer-proteolysis-targeting chimera-conjugated pH/esterase B sequence-responsive NPs,83 biodegradable reduction-responsive NPs,84 and pH-sensitive nanodelivery systems85 constitute representative intelligent responsive platforms that offer innovative strategies for cancer therapeutics. Furthermore, amorphous calcium carbonate-based intelligent nanoplatforms capable of achieving spatiotemporally controlled release of lipophilic drugs have demonstrated substantial potential for treatment of osteoporosis.86 Nanodelivery of Combination Drug Therapies Nanodelivery of combination drug therapies enables synergistic interactions among multiple therapeutic agents to enhance treatment efficacy while concurrently reducing adverse effects and drug resistance. Isoniazid and fluoxetine covalently conjugated with multi-walled carbon nanotube nanofluids have demonstrated enhanced drug delivery efficiency and elimination of drug resistance in vitro, exhibiting substantial therapeutic potential against Mycobacterium tuberculosis infection.87 Hyaluronic acid-based bionanomaterials,88 nanosystems synergistically integrating chemodynamic therapy,89 and cationic liposomal formulations co-delivering gemcitabine and ribonucleotide reductase subunit 2-targeting small interfering RNA90 have all achieved synergistic antitumor effects with favorable toxicity profiles in combination cancer therapy through the ratiometric delivery of agents operating via distinct mechanisms of action. The GLUT-1-mediated targeted delivery system transports anti-inflammatory baicalein and pro-apoptotic p53 specifically into pulmonary arterial smooth muscle cells. Baicalein suppresses local inflammatory responses, while nuclear-translocated p53 activates apoptotic pathways to eliminate excessively proliferative pathological smooth muscle cells.71 The two agents synergistically curb inflammation and aberrant vascular proliferation, thereby ameliorating pulmonary arterial hypertension. Bosentan-Chlorella nano-cocrystals integrate ET-1 receptor antagonism and anti-inflammatory therapy. Preferentially targeting pulmonary endothelium, they restore endothelial dysfunction synergistically, reduce pulmonary arterial pressure and suppress vascular remodeling via blocking the ET-1/NF-κB/ICAM-1/TNF-α/IL-6 signaling axis.7 Nanodelivery Strategies for Personalized and Precision Medicine Nanodelivery strategies for personalized and precision medicine enable the design of customized nanomedicines based on the pathological and genetic profiles of the patient, thereby achieving enhanced therapeutic efficacy. Although precision medicine relies on molecular detection and genetic analysis to achieve individualization, clinical application remains constrained by pharmacological challenges, including toxicity and drug resistance. Recently, drug delivery materials and methodologies have advanced to enable the modulation of pharmacological parameters without compromising the intended therapeutic activity at molecular targets. Consequently, the integration of precision therapeutics with drug delivery strategies holds promise to realize individualized, efficacious, and low-toxicity treatment regimens.91 Kazufumi et al applied PLGA NPs, liposomes, and metal NPs for treatment of PAH, which demonstrated that NCs can enhance pulmonary retention and cellular uptake through size optimization and surface charge modulation (eg, cationic functionalization). However, personalized design necessitates consideration of drug release kinetics and interpatient metabolic variability to achieve precision treatment.92 Manners et al,82 reviewed loading relevant therapeutic agents into NCs, which achieved personalized design objectives, such as prolonged pharmacological action and enhanced targeting specificity, thereby providing novel directions to improve the therapeutic outcomes of PAH while reducing adverse effects. Yin et al,93 developed a battery-free, chip-free, flexible nanofluidic intracellular delivery patch capable of targeted drug payload delivery to visceral organs, which exhibited high efficiency, safety, and controllability in models of breast cancer, acute liver injury, and tumor progression. Tian et al,94 proposed a “barcode” targeting approach that enables selective interactions between NPs and cellular phenotypes. NPs possess the potential to improve the stability and solubility of encapsulated cargos, facilitate transmembrane transport, and prolong circulation time, thereby enhancing safety and therapeutic efficacy.95 Nanotechnology enables monoclonal antibodies and small interfering RNA to overcome biological barriers, expanding the prospects for personalized medicine applications.96 Conclusions and Perspectives This review summarizes pharmacological strategies targeting inflammatory and OS pathways for PAH treatment, alongside recent advances in novel nanomedicine-based therapeutic approaches against PAH. The pathological mechanisms underlying PAH are exceedingly complex, while inflammation and OS play pivotal roles in driving disease progression. These pathological processes are implicated across multiple aberrantly expressed signaling pathways in PAH patients, promoting pulmonary vascular remodeling and culminating in cardiopulmonary failure. Consequently, the utilization of NCs for efficient and precise antioxidant intervention and inflammatory modulation holds considerable promise as an effective therapeutic strategy against PAH. Furthermore, NCs enable the co-delivery of multiple therapeutic agents, ensuring efficient drug delivery while effectively enhancing synergistic pharmacological effects, thereby facilitating multi-pathway-targeted PAH therapy. Major bottlenecks hindering clinical translation include inherent biosafety risks of nanocarriers, unsatisfactory lung-targeting efficiency, unclear long-term in vivo metabolic fate, and insufficient high-quality clinical evidence for large-scale application. Future research can be categorized into structural optimization of nanocarriers for elevated lung selectivity and biocompatibility, precise combinatorial regimens targeting the NF-κB/Nrf2/HIF-1α/BMPR2 oxidative-inflammatory axis, and progressive translational validation from preclinical animal models to standardized human clinical trials. Moving forward, the enhancement of targeting specificity and biosafety of NC-based drug delivery systems has emerged as a central developmental trend in optimizing therapeutic outcomes for PAH. Nevertheless, current research prospects remain confined to laboratory-level explorations and lack practical recommendations geared toward large-scale industrial translation and clinical transformation.